Brain Factory, Eisai sign Ravuconazole prodrug license agreement

As per the terms of the agreement, Eisai is expected to grant Brain Factory the exclusive rights to develop, commercialise, and sublicense ravuconazole prodrug in Japan as an ethical antimycotic for treating all types of fungal infections with the exception of Chagas disease.

Discovered and developed by Eisai, Ravuconazole is the active ingredient in the prodrug which is an antifungal agent.

The compound covered under this agreement is reported to have improved solubility and bioavailability after converted to a dihydrogen phosphonoxy methoxy derivative modified prodrug.

Further, Brain Factory plans to move forward with the development of the compound, including seeking collaboration with outside partners, as a treatment for fungal infections with a particular focus on onychomycosis (fungal infection of the nail).

Under the pact, Brain Factory and Eisai will work in close cooperation to bring a new treatment option to market as early as possible in an effort to address the unmet medical needs of people suffering from fungal infections.